Phase 1 Study of BIIB022 (Anti-IGF-1R Monoclonal Antibody) in Relapsed/Refractory Solid Tumors

A Phase 1, Open Label, Dose Escalation Study of BIIB022 (Anti-IGF-1R Monoclonal Antibody) in Subjects With Relapsed or Refractory Solid Tumors

Phase 1, open-labeled, dose escalation safety and tolerability study for the treatment of subjects with relapsed or refractory solid tumors.

Inclusion Criteria:

• Age 18 years or older at the time of informed consent
• Relapsed or refractory solid tumors following standard therapy.
• ECOG Performance Status 0 or 1.

Exclusion Criteria:

• History of insulin-dependent diabetes, type 2 diabetes, or hemoglobin A1c >6% at screening.
• History of myocardial infarction within 12 months prior to Day 1 or chronic heart failure.
• Known central nervous system or brain metastases.
• Prior anti-IGF-1R therapy of any kind.

Other protocol-defined inclusion/exclusion criteria may apply.